Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
(R)-Hydroxy Des(boric acid) Bortezomib is an impurity in the synthesis of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
?您的位置：
